Table 3. Indications for AOX therapy.
| SN | Indications for AOX therapy | Self-reported responses | |
|---|---|---|---|
| A (n=1,260) | Prescription of the antioxidants for the treatment of male infertility | ||
| No, I never do so | 182 (14.4) | ||
| Yes, but only for specific groups of patients | 528 (41.9) | ||
| Yes, I routinely do so | 550 (43.7) | ||
| Total | 1,260 (100) | ||
| B (n=1,039) | Clinical conditions treated | ||
| Risk factors for oxidative stress (obesity, age, smoking) | 707 (68.0) | ||
| Idiopathic oligoasthenoteratozoospermia | 659 (63.4) | ||
| Unexplained infertility | 651 (62.6) | ||
| Isolated asthenozoospermia | 629 (60.5) | ||
| Isolated teratozoospermia | 501 (48.2) | ||
| Isolated oligozoospermia | 479 (46.1) | ||
| Varicocele | 429 (41.3) | ||
| Increased SDF | 377 (36.3) | ||
| Empirically before assisted conception | 536 (51.6) | ||
| Necrozoospermia | 287 (27.6) | ||
| Azoospermia | 166 (16.0) | ||
| Other | 11 (1.1) | ||
| Altered seminal oxidative stress markers | 7 (0.7) | ||
| Genital tract infection/inflammation | 7 (0.7) | ||
| C (n=1,039) | Duration of antioxidant treatment (mo) | ||
| <3 | 83 (8.0) | ||
| 3 | 454 (43.7) | ||
| 3–6 | 401 (38.6) | ||
| 6–9 | 27 (2.6) | ||
| Indefinitely, until achieving conception | 74 (7.1) | ||
Values are presented as number (%).
(A) Prescription of AOX in clinical management of male infertility, (B) clinical conditions treated (percentage calculated based on the total number of participants answering this multiple option question), and (C) duration of treatment.
SN: serial number, AOX: antioxidant, SDF: sperm DNA fragmentation.